New York, Feb 6, 2026, 15:33 EST — Regular session
Haemonetics Corporation shares slumped roughly 7% Friday, despite the medical device company raising its full-year profit and cash flow forecast after posting quarterly numbers. The stock traded at $60.46 in the afternoon, down $4.56.
This is important for Haemonetics, which wants to prove its core franchises have momentum beyond last year’s portfolio shakeups. Investors, focused closely on its hospital segment, have pushed the stock around on every update—guidance changes tend to jolt it fast.
Haemonetics makes blood management gear for hospitals and supplies for plasma collection. Lately, investors have zeroed in on the company’s “organic” growth rates, a figure that removes the impact of currency shifts and acquisitions, as a key signal of underlying performance.
Haemonetics posted third-quarter revenue of $339.0 million on Thursday, a 2.7% dip versus last year, but adjusted EPS improved to $1.31 from $1.19. Gross margin reached 59.7%, a 420 basis-point increase—each basis point equals one-hundredth of a percent. Free cash flow climbed to $74.2 million. The company bumped its fiscal 2026 adjusted EPS target to $4.90-$5.00 and now sees free cash flow in the $200-$220 million range. CEO Chris Simon pointed to “revenue growth, margin expansion, and cash flow” as evidence of core business strength. SEC
On the call, executives highlighted solid results from Blood Management Technologies, but Interventional Technologies continued to weigh on performance. Interventional tech sales dropped 12% for the quarter, with management blaming weaker demand for esophageal cooling as pulsed field ablation (PFA) picks up steam. Plasma revenue climbed 3% to $139 million after cycling past last year’s “customer transition” issues. CFO James D’Arecca warned of an upcoming headwind from interest and taxes as the company prepares to pay off $300 million in zero-coupon convertible notes. The Motley Fool
Wall Street wasn’t letting up. Citigroup’s Joanne Wuensch maintained her neutral stance on the stock, but on Friday she slashed her price target to $75 from $88, a report from GuruFocus showed.
The company is ramping up its vascular closure efforts before rolling out PerQseal Elite in the U.S.—a segment already packed with heavyweight medtech competitors. As a result, quarterly performance in the hospital channel isn’t easy to call.
The flip side is clear enough: should interventional softness persist, hospital growth may linger around the bottom of management’s guidance, regardless of plasma performance. A postponed major product debut or a steeper drop in procedure-driven demand could deliver another blow to revenue.
With March approaching, all eyes are on Haemonetics as $300 million in convertible notes hit maturity. The company plans to cover the payment with a mix of available cash and draws on its revolving credit line. Traders will be tracking any updates on when PerQseal Elite might launch in the U.S.—and scrutinizing signs of stability, or lack thereof, in the interventional segment heading into the next quarter.
